Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes

Sci Rep. 2023 Aug 9;13(1):12948. doi: 10.1038/s41598-023-39243-x.

Abstract

Hypoglycemia in type 1 diabetes associates with changes in the pancreatic islet α cells, where the receptor for advanced glycation end products (RAGE) is highly expressed. This study compared islet RAGE expression in donors without diabetes, those at risk of, and those with type 1 diabetes. Laser-dissected islets were subject to RNA bioinformatics and adjacent pancreatic tissue were assessed by confocal microscopy. We found that islets from type 1 diabetes donors had differential expression of the RAGE gene (AGER) and its correlated genes, based on glucagon expression. Random forest machine learning revealed that AGER was the most important predictor for islet glucagon levels. Conversely, a generalized linear model identified that glucagon expression could be predicted by expression of RAGE signaling molecules, its ligands and enzymes that create or clear RAGE ligands. Confocal imaging co-localized RAGE, its ligands and signaling molecules to the α cells. Half of the type 1 diabetes cohort comprised of adolescents and a patient with history of hypoglycemia-all showed an inverse relationship between glucagon and RAGE. These data confirm an association between glucagon and islet RAGE, its ligands and signaling pathways in type 1 diabetes, which warrants functional investigation into a role for RAGE in hypoglycemia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Diabetes Mellitus, Type 1* / genetics
  • Glucagon
  • Glucagon-Secreting Cells* / metabolism
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Hypoglycemia*
  • Ligands
  • Receptor for Advanced Glycation End Products* / metabolism

Substances

  • Glucagon
  • Glycation End Products, Advanced
  • Ligands
  • Receptor for Advanced Glycation End Products
  • AGER protein, human